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regulatory proteins in cattle infected with bovine leukemia virus
Abstract
The polymerase chain reaction was used to detect and characterize low-abundance bovine leukemia virus
(BLV) mRNAs. In infected cattle we could detect spliced mRNA with a splice pattern consistent with a Tax/
Rex mRNA, as well as at least four alternatively spliced RNAs. Two of the alternatively spliced mRNAs
encoded hitherto unrecognized BLV proteins, designated RIII and GIV. The Tax/Rex and alternatively spliced
mRNAs could be detected at their highest levels in BLV-infected cell cultures; the next highest levels were
found in samples from calves experimentally infected at 6 weeks postinoculation. Alternatively spliced
mRNAs were also expressed, albeit at lower levels, in naturally infected animals; they were detected by a
nested polymerase chain reaction. Interestingly, the GIV mRNA was specifically detected in naturally infected
cows with persistent lymphocytosis and in two of five calves at 6 months after experimental infection with
BLV. Furthermore, the calf with the strongest signal for GIV had the highest lymphocyte counts. These data
may suggest a correlation between expression of the GIV product and development of persistent
lymphocytosis. Some of the donor and acceptor sites in the alternatively spliced mRNAs were highly unusual.
The biological mechanisms and significance of such a choice of unexpected splice sites are currently unknown.
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The polymerase chain reaction was used to detect and characterize low-abundance bovine leukemia virus
(BLV) mRNAs. In infected cattle we could detect spliced mRNA with a splice pattern consistent with a Tax/Rex
mRNA, as well as at least four alternatively spliced RNAs. Two of the alternatively spliced mRNAs encoded
hitherto unrecognized BLV proteins, designated RI and GIV. The Tax/Rex and alternatively spliced mRNAs
could be detected at their highest levels in BLV-infected cell cultures; the next highest levels were found in
samples from calves experimentally infected at 6 weeks postinoculation. Alternatively spliced mRNAs were also
expressed, albeit at lower levels, in naturally infected animals; they were detected by a nested polymerase chain
reaction. Interestingly, the GIV mRNA was specifically detected in naturally infected cows with persistent
lymphocytosis and in two of five calves at 6 months after experimental infection with BLV. Furthermore, the
calfwith the strongest signal for GIV had the highest lymphocyte counts. These data may suggest a correlation
between expression of the GIV product and development of persistent lymphocytosis. Some of the donor and
acceptor sites in the alternatively spliced mRNAs were highly unusual. The biological mechanisms and
significance of such a choice of unexpected splice sites are currently unknown.
Bovine leukemia and lymphosarcoma, an economically
important disease of cattle (103), attracted attention early in
this century. In several European countries, the finding of
clusters of herds with a high incidence of leukemia and
lymphosarcoma suggested an infectious etiology. Neverthe-
less, bovine leukemia virus (BLV) was not isolated until
1969 (70), and it was shown to be the infectious agent of
persistent lymphocytosis and chronic leukemia and lym-
phoma in cows. BLV belongs to the oncovirus group of the
family Retroviridae and is structurally related to human
T-cell lymphotropic virus types I and II (HTLV-I and
HTLV-II), agents associated with adult T-cell leukemia and
perhaps with hairy T-cell leukemia in humans (43, 46, 96, 99,
110, 111). However, BLV causes B-cell proliferation and
neoplasia whereas HTLV causes T-cell neoplasia. An exact
characterization of the BLV-induced tumor cells has not yet
been established. They seem to belong to the B-lymphocyte
lineage, and their blastlike morphology and reactivity to
heavy-chain immunoglobulin M suggest that they most prob-
ably are pre-B cells (21, 35, 40).
BLV and HTLV have no known oncogene incorporated in
their genomes and apparently have no preferred integration
sites in tumor cells, suggesting that their mechanisms for
tumor initiation are different from those of other oncogenic
retroviruses. BLV and HTLV genomes have a special X
region located between the env region and the 3' long
terminal repeat (LTR) (81, 89, 96, 99), and it has been
speculated that expression of this X region is somehow
* Corresponding author.
involved in the early events of tumorigenesis (21, 58). The X
region contains several open reading frames (ORFs), one of
which encodes a trans-activating protein, Tax (36, 46, 47, 84,
85, 87, 88), and another encodes the Rex protein, involved in
promoting the expression of viral structural proteins (1, 37,
51, 79, 88). The mRNAs and protein products of these two
genes have been characterized for both HTLV and BLV (1,
36-38, 46, 47, 51, 79, 84, 85, 88), and the functional roles of
these proteins in gene regulation of the two viruses have
been established.
Transcription of the BLV genome in animals with chronic
infection or with tumors is nearly undetectable by conven-
tional techniques (59, 60, 65), although the persistent pres-
ence of antibodies to viral proteins suggests a continuous,
albeit low-level, production of viral proteins (21, 56, 75, 87).
Transcription of the Tax/Rex mRNA has recently been
shown in HTLV-infected individuals and in BLV-infected
cattle by using the sensitive technique of reverse tran-
scriptase-polymerase chain reaction (PCR) (44, 55, 62, 98).
It was originally proposed that, in addition to the Tax and
Rex ORFs, both HTLV and BLV may potentially express
several other small ORFs in the X region (80, 81, 89, 96,
111). These ORFs have been termed XBL-III and XBL-IV
for BLV and pXI and pXII for HTLV. Proteins encoded by
these genes would have to be translated from mRNAs that
are spliced differently from the mRNA for the Tax and Rex
proteins (88, 108, 109). Alternative splicing of the small
multiple-spliced mRNAs encoding regulatory proteins of the
lentiviruses, especially human immunodeficiency virus
(HIV), is well established (8, 14, 41, 48, 83, 93-95), and
complex splicing has also been shown for the spumaretrovi-
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ruses (73). Recently, complex splicing was shown for
HTLV, together with preliminary data on BLV (15, 27, 42,
76). These data indicated that complex splicing is a feature of
the BLV/HTLV group of viruses.
In the present study we have characterized the pattern of
mRNA splicing in BLV-infected animals and have attempted
to correlate the findings with the development of clinical
disease. In infected cattle we could detect spliced mRNA
with a splice pattern consistent with a Tax/Rex mRNA, as
well as at least four alternatively spliced RNAs. Two of the
alternatively spliced mRNAs encoded hitherto unrecognized
BLV proteins, designated RIII and GIV, from the XBL-III
and XBL-IV ORFs, respectively. The GIV mRNA was
specifically detected in naturally infected cows with persis-
tent lymphocytosis and in two of five calves at 6 months after
experimental infection with BLV. Interestingly, the calf with
the strongest signal for GIV had the highest lymphocyte
counts. Taken together, the data may suggest a correlation
between expression of the GIV product and development of
persistent lymphocytosis.
MATERIALS AND METHODS
Cells and virus. Bovine kidney (MDBK) cells (ATCC CCL
22), primary fetal bovine lung (FBL) cells (107), and feline
kidney (CRFK) cells (31) were used for the in vitro experi-
ments. A chronically BLV-infected continuous fetal lamb
kidney cell line (FLK-BLV) was kindly provided by Janice
Miller, National Animal Disease Center, Ames, Iowa. Cells
were grown in Dulbecco's minimum essential medium sup-
plemented with 10% fetal calf serum, antibiotics, and glu-
tamine.
Animals. Eight colostrum-deprived Holstein calves, 4 to 6
months of age, were repeatedly tested and found to be free of
bovine retroviruses, including bovine immunodeficiency-like
virus, bovine spumaretrovirus, and BLV. Five of the eight
calves were inoculated intravenously with 107 peripheral
blood mononuclear cells (PBMC) from a BLV-infected cow
with persistent lymphocytosis (cow 9321), while three age-
matched control calves were inoculated with 107 PBMC
from a retrovirus-free calf. Additional in vivo samples were
obtained from an age-matched Holstein calf naturally in-
fected with BLV (calf 357) and from two cows naturally
infected with BLV (cows 9321 and 9324). Both cows had
exhibited persistent lymphocytosis for more than 2 years.
Virus isolation. Blood samples were collected three times
per week during the first 3 months postinoculation (p.i.) and
at 4- to 6-week intervals thereafter. At 2, 6, 19, and 28 weeks
p.i., whole blood was collected into acid citrate dextrose and
PBMC were isolated as described previously (25, 86). For
isolation of BLV, 107 PBMC were cocultivated with 5 x 105
FBL cells in the presence of Polybrene (25, 107). Cells were
subcultured once, fixed in 70% acetone-30% methanol, and
tested for the presence of BLV by using an indirect immu-
nofluorescence assay similar to that described earlier (25).
For these studies, we used a 1:100 dilution of polyclonal
BLV antiserum obtained from a sheep experimentally in-
fected with BLV as the primary antibody and a 1:30 dilution
of fluoresceinated rabbit anti-sheep immunoglobulin G
(Jackson Immunoresearch Labs, West Grove, Pa.) as the
secondary antibody.
In situ hybridization. Fragments spanning the full length of
the BLV913 infectious clone (kindly provided by David
Derse, Frederick Cancer Research Facility, Frederick, Md.)
were subcloned into a transcription vector based on the SP6
and T7 phage promoters by using previously described
techniques (2, 5, 105). The BLV DNA and RNA contents in
infected cells were measured by using 35S-labeled RNA
probes and in situ hybridization as described previously (4,
5, 7, 105). Preliminary studies have shown that this strategy,
paired with image analysis, gives excellent quantitative
results on BLV-infected cells (106a).
Samples for RNA analysis. RNA samples analyzed con-
sisted of total RNA extracted from FLK-BLV cells, from
uninfected MDBK cells, and from bovine PBMC. Samples
were collected from experimentally infected animals at 2, 6,
and 28 weeks after infection.
PBMC were isolated as described above. To avoid in vitro
activation of BLV transcription, the PBMC were not in
contact with heterologous serum and were processed as fast
as possible. Total RNA was extracted by the guanidine
thiocyanate method followed by centrifugation through a
cesium chloride cushion as described previously (3). Total
cellular DNA was extracted from the interphase of the
cesium chloride cushion.
PCR amplification. Data on BLV infection have suggested
that ordinary Northern (RNA) blotting or cDNA mapping
can be difficult or impossible because the specific mRNAs in
question are of very low abundance. Therefore, single-
stranded cDNA synthesis and amplification by PCR fol-
lowed by cloning and sequencing of the products were used.
PCR amplifications were done on single-stranded cDNA
from control and BLV-infected cells by using selected pairs
of oligonucleotide primers, a commercially available temper-
ature cycler, and a standard protocol supplied by the man-
ufacturer (Perkin Elmer Cetus, Norwalk, Conn.) or a proto-
col with minor modifications (6, 23, 45). Samples (1 ,ug) of
total RNA were converted into cDNA by using oligo(dT) as
the primer and avian myeloblastosis virus reverse tran-
scriptase in a volume of 20 RI under the conditions described
by the manufacturer (Promega Corp., Madison, Wis.). A
10-,ul sample of this single-strand cDNA was then used
directly for PCR in a 100-,ul total volume under standard
conditions (Perkin Elmer Cetus) involving 35 cycles of
denaturation at 94°C for 1 min, annealing at 50°C for 1 min,
and extension at 72°C for 2 min. Nested PCR was done for
another 35 cycles on 1-pI samples from the first PCR
amplifications by using internal primers and standard condi-
tions. For PCR analysis of cDNA from BLV-infected cells,
we constructed nine oligonucleotide primers each 20 to 22
nucleotides (nt) in length. The sequences, locations in the
BLV genome (89), and designations of the oligonucleotide
primers are as follows: BLV221, 5'-TTCTCCTGAGACCCT
CGTGC-3' (nt 221 to 240); BLV251, 5'-GTCCTGAGCTCTC
TTGCTCC-3' (nt 251 to 270); BLV53OC', 5'-TGTTTGCCG
GTCTCTCCTGG-3' (nt 530 to 511); BLV4761, 5'-CGCTCT
CCTGGCTACTGACC-3' (nt 4761 to 4780); BLV6831C', 5'-A
GGTATCTCTAGAAAGGGTG-3' (nt 6831 to 6812); BLV
6900C', 5'-GGAGGTTGCGGCTCGAGCITA-3' (nt 6900 to
6881); BLV7140C', 5'-GCAGCCGTTGTGGAAACGGA-3'
(nt 7140 to 7121); BLV7221C', 5'-CGTTATCAGGTAATG
GATCCCG-3' (nt 7221 to 7200); BLV7557C', 5'-AAGTGA
AACCGGGCCGGGCT-3' (nt 7557 to 7538). The locations of
these primers are shown in Fig. 1.
Samples of amplified DNA were run on 3 to 4% agarose
gels, and the identity of the bands was confirmed by hybrid-
ization to specific probes radiolabeled as described previ-
ously (3, 6, 17, 23, 45). For use as probes, we subcloned
several segments of the BLV913 full-length clone of BLV
(Fig. 1).
Cloning and nucleotide sequence analysis. Samples of am-
plified DNA were extracted with phenol and chloroform,
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FIG. 1. Schematic representation of the BLV provirus. All numbering of nucleotides in the present report is based on the available
GenBank sequence of BLV published by Sagata et al. (89). The total proviral genome, including both LTRs, is thus 8,714 nt. The locations
of the two complete LTRs (shaded boxes), the ORFsgag, prot,pol, env, tax, rex, XBL-III, and XBL-IV are indicated. The putative cleavage
site in the env gene generating gpSl and gp3O is indicated as a vertical arrow. Regions of BLV which we have subcloned for use as probes
are indicated by thick, horizontal bars at the top of the figure. The proposed structure for the mRNA encoding Gag, Prot, and Pol is shown
as an unspliced, full-length RNA; the mRNA encoding Env is shown as a singly spliced transcript; and the mRNA encoding Tax and Rex is
shown as a doubly spliced transcript. The initiating methionines on this mRNA are shown as a vertical line for the Tax methionine and a
hatched box for the Rex methionine. The alternatively spliced mRNAs described in this paper are shown below the Tax/Rex mRNA. The
designations of the alternatively spliced mRNAs are indicated to the right, and the potential new translation products of these mRNAs are
indicated with boxes. The designation, position, and direction of the primers used for splice-specific cDNA-PCR are shown at the bottom.
digested with proteinase K, phenol-chloroform extracted
again, and precipitated with ethanol. Amplified DNAs were
then restricted with Sacl, which cuts at nt 256, 353, and 7192
in the BLV genome (89). Such restricted DNA samples were
then ligated into SacI-digested pGEM3Z (Promega) by using
standard techniques. Ligated DNA was transformed into
Escherichia coli JM109, and the colonies were screened by
using subgenomic fragments of BLV radiolabeled with 32p.
Clones that reacted with the BLV probes were digested with
selected restriction enzymes and nucleotide sequenced by
the dideoxy-chain termination method (91) with [35S]dATP
as the label as previously described (3, 6, 16, 17, 23, 45).
Templates for sequencing were double-stranded plasmid
DNAs prepared as described previously (26). The primers
used were either commercially available or BLV-specific
oligonucleotides. All regions were sequenced at least twice
in both directions. DNA sequences were analyzed by using
the Microgenie (Beckman Instruments) and the PC/GENE
(IntelliGenetics) sequence analysis programs. The nucle-
otide numbering for BLV described by Sagata et al. (89) is
used in the present paper.
Construction of expression plasmids. Functional cDNAs
were generated by ligation of the PCR-generated clones into
the SacI site of a pGEM4Z plasmid containing BLV se-
quences from the Sacl site at nt 7192 to the EcoRI site at nt
7924. Functional inserts were cut out of these plasmids by
SmaI, which cuts in the multiple cloning site 5' to the BLV
sequences, in the middle exon at nt 4699 (for clones having
the middle exon), and at nt 7895 for subsequent subcloning
into the eukaryotic expression plasmids pRSPA-S and pSVL
(Pharmacia, Uppsala, Sweden). The pRSPA-S vector con-
tains the strong Rous sarcoma virus promoter and the splice
and polyadenylation sequences from simian virus 40 and was
kindly provided by David Derse, who also provided a Tax
expression construct in this vector (36, 37). A construct
expressing primarily Rex was constructed by PCR-generated
mutation of the Rex ATG into the sequence AAAATG-G (nt
4818 to 4824) and cloning of a construct from nt 4810 to 4871
spliced to the Rex/Tax acceptor at nt 7247 and ending at nt
7924.
Transfections and CAT assays. The above-mentioned ex-
pression constructs were transfected into CRFK cells by
using standard calcium phosphate precipitation (9) proce-
dures essentially as described previously (16). Briefly, nearly
confluent monolayers of cells in 60-mm tissue culture dishes
were cotransfected with the expression plasmids and a
BLV-LTR-CAT construct kindly provided by David Derse.
In some experiments the BLV-LTR-CAT plasmid was
cotransfected with a BLV-Tax expression plasmid (36-38) or
with the parental pRSPA-S plasmid as a negative control.
The pCATCONTROL plasmid (Promega), which contains
the simian virus 40 promoter and enhancer and the bacterial
VOL. 67, 1993
502/7157
 o
n
 April 11, 2018 by IO
W
A STATE UNIVERSITY
http://jvi.asm.org/
D
ow
nloaded from
 
42 ALEXANDERSEN ET AL.
20000
15000
10000
5:_
a)
0.
E
5000
0
15000
10000
5000
0
2 14 28 43
Weeks Post Inoculation
FIG. 2. Numbers of peripheral blood lymphocytes following
experimental inoculation. (A) Five calves inoculated with 107 PBMC
from a BLV-infected cow with persistent lymphocytosis. (B) Three
control calves inoculated with 107 PBMC from a retrovirus-free calf.
Numbers represent individual animals.
chloramphenicol acetyltransferase (CAT) gene, served as a
useful monitor of transfection efficiency. Lysates were ana-
lyzed for CAT activity by a liquid scintillation assay essen-
tially as described previously (9).
Experiments were done in duplicate by using reaction
times in the linear range of the assay and equivalent amounts
of protein.
In vitro transcription and translation. The functional
cDNA clones in pGEM4Z described above were linearized
with EcoRI, which cuts at nt 7924, or ClaI, which cuts at nt
7318 immediately downstream of the XBL-III and XBL-IV
ORFs (Fig. 1). Capped runoff transcripts were synthesized
by using T7 RNA polymerase as specified by the manufac-
turer (Stratagene, La Jolla, Calif.). In vitro translations were
done in a nuclease-treated rabbit reticulocyte lysate (Pro-
mega) in the presence of [3H]leucine or [35`S]cysteine. The
resulting proteins were analyzed by immunoprecipitation
and sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE).
Rabbit antipeptide antisera. A 14-amino-acid peptide (AL
RDPLPDNDKIIS) from the XBL-IV ORF, with a high
probability of containing an antigenic site, was synthesized
at the Iowa State University Peptide Synthesis Facility. A
cysteine was added to the N terminus to facilitate cross-
linking to keyhole limpet hemocyanin (Sigma). Cross-linking
was kindly performed by Arne Holm, Department of Chem-
istry, Royal Veterinary University, Denmark. Antipeptide
antibodies were produced in rabbits by subcutaneous injec-
tion of 500 ,ug of keyhole limpet hemocyanin-peptide conju-
gate in Freund's complete adjuvant followed by two booster
injections of the conjugate in incomplete adjuvant. An anti-
C-terminal BLV-Rex antibody (77) was kindly provided by
Kathryn Radke, Department of Avian Sciences, University
of California, Davis.
Immunoprecipitation. For immunoprecipitation, 10 ,ul of in
vitro-translated products was mixed with 190 ,ul of RIPA
buffer (20 mM Tris [pH 7.3], 150 mM NaCl, 1 mM EDTA, 2
mM phenylmethylsulfonyl fluoride, 1% Nonidet P-40, 0.5%
sodium deoxycholate, 0.1% SDS, 0.5 U of aprotinin per ml,
and 5 p,g of leupeptin per ml). Serum (1 or 10 ,ul) was added,
and the mixture was incubated at 4°C for 16 h with agitation
before addition of 50 ,ul of 50% protein A-Sepharose Fast
Flow (Pharmacia) and another incubation for 3 h. After
extensive washing of the precipitates, these were analyzed
by SDS-PAGE. Gels were fixed, soaked in Amplify (Amer-
sham, Aylesbury, Buckinghamshire, England), dried, and
exposed to X-ray film as described previously (24).
RESULTS
Clinical disease and virus replication. All five BLV-infected
calves experienced a mild, transient increase in lymphocyte
numbers at 2 to 4 weeks p.i. (Fig. 2A). A similar increase
was not observed in the control animals (Fig. 2B). A second
phase of increased lymphocyte numbers (10,000 to 12,000
lymphocytes per ,ul of whole blood) was observed in calf 353
at 30 weeks p.i. and persisted through 43 weeks p.i. (Fig.
2A). Virus was recovered from all experimentally infected
calves through 28 weeks p.i., although the levels of virus
replication appeared to be variable (Table 1). Larger num-
bers of BLV-infected cells were consistently observed in calf
353, whereas smaller numbers of infected cells were charac-
teristic of calf 351. Temporal changes in the level of virus
replication were observed for the other calves. Over time,
there was a decrease in the number of infected cells in calf
355, whereas increased numbers of BLV-infected cells were
observed in calf 352 (Table 1).
Levels of virus replication and expression in PBMC were
TABLE 1. Quantitation of BLV in infected cattle
No. of BLV syncytia/
10-5 PBMCa No. of hybridization-
Animal positive cells/105
8 wk 19 wk PBMC (19 wk p.i.)
p.iC p.i.d
351e 32 11 0
352e 26 >500 50-100
353e 740 >500 50-100
354e 720 NW ND
355e 560 54 1
93219 ND >500 20,000
a The number of BLV-induced syncytia in FBL cells following cocultiva-
tion with PBMC isolated from BLV-infected calves at 8 and 19 weeks p.i.
b Quantitation of BLV-positive cells by in situ hybridization was done on
serum-treated PBMC hybridized with an antisense BLV probe as described in
the text.
c FBL cells were cocultured with 10-fold serial dilutions of PBMC. After 4
days, the cells were fixed and stained for the presence of BLV-induced
syncytia by immunofluorescence as described in the text.
d FBL cells were cultured with PBMC, subcultured once, and stained for
the presence of BLV-induced syncytia by immunofluorescence as described
in the text.
e Calves inoculated with 107 PBMC from a BLV-infected cow with persis-
tent lymphocytosis.
f ND, not done.
g Cow naturally infected with BLV that had been persistently lymphocy-
totic for more than 2 years. Samples from this cow were analyzed at the same
time as the 19-week p.i. samples from the experimentally infected calves.
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also analyzed by in situ hybridization, using full-length RNA
antisense BLV probes to detect BLV RNA. A few positive
cells could be detected in all five calves at 2 weeks p.i., but
at 6 weeks p.i. calf 351 was negative and the other four
calves had only 1 positive cell per 105 PBMC (data not
shown). PBMC from four of these calves were isolated at 19
weeks p.i. and incubated at room temperature for 4 to 6 h in
phosphate-buffered saline (PBS) alone or in PBS with 10%
fetal calf serum. PBMC from cow 9321 with persistent
lymphocytosis were incubated similarly. Cytospins were
then made and processed for in situ hybridization. Analysis
of these cytospins showed no positive cells in any of the calf
PBMC or in the cow PBMC incubated in PBS. After
incubation in 10% serum, no positive cells were detectable in
calf 351, but calf 355 had a single positive cell and calves 352
and 353 had 50 to 100 positive cells per 105 PBMC (0.05 to
0.1% positive cells) (Table 1). Unfortunately, PBMC from
calf 354 were not available for analysis. Analysis of PBMC
from cow 9321 that were incubated in PBS showed no
positive cells, whereas incubation in PBS with 10% fetal calf
serum induced BLV expression in approximately 20% of the
cells (Table 1). Moreover, a significant portion of the PBMC
had more than 100 grains per positive cell, in contrast to the
PBMC from experimentally infected calves, of which only a
few cells contained more than 30 grains (data not shown).
These findings indicated that the cow with persistent lym-
phocytosis had a much higher percentage of BLV-infected
cells than did the experimentally infected calves at 19 weeks
p.i. and, moreover, that these cells could be induced to
transcribe BLV at a high level. Hybridization with a BLV
sense probe showed no positive cells, indicating that the
signal detected with the antisense probe represented hybrid-
ization to BLV RNA and not to BLV proviral DNA. Thus,
the in situ hybridization analysis indicated that our proce-
dure for isolating PBMC, as expected, did not induce BLV
expression but that subsequent stimulation with serum acti-
vated expression.
Taken together, the data indicated that the largest number
of infected cells able to express BLV were present in cow
9321 followed by calves 352 and 353. Moreover, of the
experimentally infected calves, calf 353 also had the highest
lymphocyte counts.
Amplification of Tax/Rex mRNA. In initial experiments we
looked for Tax/Rex mRNA in the samples by using cDNA-
PCR amplification of sequences containing the R region
(primer BLV251) and sequences in the Tax/Rex region
(primer BLV7557C') (Fig. 1). Amplification ofRNA from the
BLV-infected cell culture, FLK/BLV, resulted in strong
bands at approximately 590 and 550 bases and a weak band
at ca. 800 bases (Fig. 3A). Amplification of RNA extracted
from leukocytes from a pool of five BLV-infected calves at 6
weeks p.i. resulted in two weak bands at 590 and 550 bases.
These two bands had approximately the same intensity (Fig.
3A). The size of the bands (550 and 590 bases) is consistent
with the presence of a Tax/Rex mRNA in the cell culture and
in the infected calves. The presence of two bands may
indicate that one of the predicted splice sites is heteroge-
neous. Probing with BLV probes spanning the Tax/Rex
region or the middle exon was positive on both bands,
whereas probing with a probe specific for the XBL-III and
XBL-IV regions (Fig. 1) was negative, indicating that the
products were amplified from genuine Tax/Rex mRNA. The
band at 800 bases seen in the FLK/BLV sample reacted with
the XBL-III/IV probe and may represent alternatively
spliced mRNAs (see below). Amplification of RNA isolated
from a cow with persistent lymphocytosis (cow 9321) re-
A
1 2 C
800 bp-
590 bp-
550 bp-
B
1 2 3 C
610 bp- ;
400bp-_
FIG. 3. Southern blot analysis of PCR-amplified cDNAs. Sam-
ples were electrophoresed into agarose gels, Southern blotted onto
nylon filters, and hybridized with a full-length BLV probe as
described in the text. The sizes of amplified products are indicated
in base pairs. (A) PCR with primers BLV251 and BLV7557C'. (B)
Nested PCR with primers BLV251 and BLV7557C' followed by
primers BLV4761 and BLV7557C'. Lanes: 1, FLK/BLV; 2, calves
experimentally infected with BLV at 6 weeks p.i.; 3, calf 357
naturally infected with BLV; C, control calves.
sulted in bands of approximately 590 and 400 nt (data not
shown). Probing of these bands indicated that the 590-nt
band represented genuine Tax/Rex mRNA while the 400-nt
band lacked the middle exon, comparable to a truncated Rex
mRNA described for HTLV (15, 42, 76). Amplification by
using the same primers on RNA isolated from PBMC from a
naturally BLV-infected calf, another naturally BLV infected
cow (cow 9324) with persistent lymphocytosis, a group of
noninfected calves, and control cell cultures was consis-
tently negative (Table 2).
Nested PCR (nested in only one side) was then performed
on the previous PCR products by using primer BLV4761
(located in the middle exon) and primer BLV7557C'. This
resulted in a strong band around 400 bases and a very weak
band at 610 bases in the samples from the BLV-infected cell
cultures, the experimentally infected calves at 6 weeks p.i.,
the naturally BLV-infected calf (Fig. 3B), the two naturally
infected cows with persistent lymphocytosis, and four of five
experimentally infected calves (Table 2). The strong bands
were consistent with abundant amplification of a Tax/Rex
mRNA with a theoretical size of ca. 410 bases. This band
was mapped to the middle exon region and the Tax/Rex
region by using subgenomic BLV probes (data not shown).
The fact that we detected only one strong Tax/Rex amplified
band by using these primers may indicate that the heteroge-
neity we observed when using primers BLV251 and
BLV7557C' is due to a heterogeneity in the first splice (Fig.
1). The weak band at 610 bases could be from amplification
of an XBL-IV mRNA with a theoretical product around 600
to 650 bases (see below). The intensity of this band (Fig. 3B)
was, however, too weak to be convincingly mapped with
subgenomic probes. The control calves gave consistently
negative results.
PCR samples from the FLK/BLV cell culture and cow
9321 with persistent lymphocytosis were reamplified with
primers located at nt 4802 to 4834 (this primer adds a SmaI
site at nt 4810) and nt 7324 to 7350 (this primer adds a SmaI
site at nt 7341). The amplified products were cut with SmaI
and cloned into pGEM3Z. Two clones from the FLK/BLV
cell culture and six from cow 9321 were sequenced, and all
eight clones had nt 4871 spliced to nt 7247 and thus repre-
sented the BLV Tax/Rex splice described previously (108).
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TABLE 2. Results of cDNA-PCR analysis of BLV samples
Detection ofa:
Sample Alternative Clinical stageb
spliced'
FLK-BLVe +++ +++ NAf
Control calve - - Normal
J3LV2wkp.j.h ++ ++ NA
BLV 6 wk p.i.h +++ +++ NA
BLV 28 wk p.i.h
351 - - Asymptomatic
352 + + Asymptomatic
353 + + + + Lymphocytosis
354 + + ++ Asymptomatic
355 + + Asymptomatic
Cow 9321'
Sample 1 +++ ++ Lymphocytosis
Sample 2 +++ ++ Lymphocytosis
Cow 9324' + + + + Lymphocytosis
Calf 357
Sample 1 ++ ++ Asymptomatic
Sample 2 + + ++ Asymptomatic
a The different samples and the detection of Tax/Rex or alternative spliced
mRNA are indicated. Symbols: +++, samples are positive by direct PCR;
+ +, strong positive reaction by nested PCR; +, weak but consistent positive
reaction in nested PCR; -, negative reaction by Southern blot of both direct
and nested cDNA-PCR reactions.
b In vivo samples were collected from control or BLV-infected animals.
The clinical outcome of BLV infection is listed as either asymptomatic or
lymphocytosis (lymphocytes consistently above 10,000/,l of blood).
Tax/Rex mRNA was amplified by using primers in the LTR or middle
exon paired with primer BLV7557C' in the Tax/Rex ORF.
d Alternatively spliced mRNA containing sequences in the XBL-IV or
XBL-III ORF was detected by cDNA-PCR with specific primers as described
in the text. Southern blots were probed with a subgenomic fragment of BLV
containing sequences in the XBL-IV and XBL-III ORFs.
I A chronically BLV-infected cell line.
f NA, not applicable.
g Control calves were inoculated with PBMC from a clinically normal,
retrovirus-free calf. PBMC from the three animals were pooled, and RNA was
extracted and analyzed at 11, 16, and 20 weeks p.i.
h Five calves experimentally infected with PBMC from cow 9321. PBMC
collected at 2 and 6 weeks p.i. were pooled for RNA isolation. At 28 weeks
p.i., RNA was isolated from indIvidual animals as indicated.
i Cows naturally infected with BLV and persistently lymphocytotic for
more than 2 years. RNA was extracted from PBMC from cow 9324 once and
from cow 9321 twice with a 3-month interval (samples 1 and 2).
i Calf 357 was naturally infected with BLV. PBMC were sampled at
approximately 4 months (sample 1) and 5 months (sample 2) of age.
Taken together, these results demonstrated the presence of
low levels of Tax/Rex mRNA in the in vivo samples, similar
to recently published results (55), and established the valid-
ity of our techniques.
mRNA containing sequences in the XBL-IV or XBL-III
ORF. To establish whether BLV-encoded mRNAs alterna-
tively spliced to contain XBL-IV or XBL-III coding se-
quences (Fig. 1), we designed a series of oligonucleotide
primers to detect alternatively spliced mRNAs by using
PCR. First, we attempted specific amplification of an mRNA
potentially containing the XBL-IV ORF (nt 7044 to 7307).
Direct cDNA-PCR with primers BLV251 and BLV714OC'
resulted in amplification of one strong band and several weak
bands in amplified RNA from FLK/BLV cell cultures (Table
2). A weaker band could be detected in amplified RNA
isolated 6 weeks after experimental BLV infection of calves.
Importantly, bands were positive with probes spanning the
LTR region, the middle exon, and the XBL-IV region but
negative with a probe in the Tax/Rex region (because the
primer ends at nt 7140). Amplifications of RNA from the
300 bp- *^
200 bp-
FIG. 4. Southern blot analysis of PCR-amplified cDNAs. Total
RNA was converted to cDNA and subjected to nested PCR by using
primers BLV251 and BLV7557C' followed by primers BLV4761 and
BLV7140C'. Samples of the PCR products were electrophoresed
into agarose gels, Southern blotted onto nylon filters, and hybridized
with a full-length BLV probe as described in the text. Approximate
sizes are indicated in base pairs. Lanes: C, control calves; 1,
FLK/BLV; 2, calves experimentally infected with BLV at 6 weeks
p.i.; 3, calf 357 naturally infected with BLV; 4, calf 353 experimen-
tally infected with BLV at 28 weeks p.i.; 5, calf 354 experimentally
infected with BLV at 28 weeks p.i.; 6, cow 9321 with BLV-induced
persistent lymphocytosis.
naturally infected animals, from the control animals, and
from control cell cultures were negative by direct PCR
(Table 2).
Nested PCR was then done on samples already amplified
with the BLV251 and BLV7557C' primer sets. For these
amplifications we used primer BLV4761 paired with
BLV7140C' or BLV7221C'. Both set of primers resulted in
amplified products in the samples from FLK/BLV, in the
pool of experimentally infected calves at 2 and 6 weeks p.i.,
in four of five calves at 28 weeks p.i., in the naturally
infected calf, and in the two cows with persistent lympho-
cytosis (Table 2). No bands were detected in amplified RNA
from noninfected calves or from control cell cultures (Table
2). The number and size of bands varied among the positive
samples (Fig. 4) but were consistent in repeated experi-
ments. Furthermore, amplified bands consistently reacted
with a probe containing the XBL-III/IV ORFs. These results
indicated that alternatively spliced mRNAs that potentially
could encode proteins were present at low levels in BLV-
infected cell cultures and cattle.
To examine whether we could detect alternatively spliced
mRNA specifically containing sequences in the XBL-III
ORF (nt 6742 to 7098), we performed cDNA-PCR with
primers located in this region. Direct PCR with primer
BLV251 paired with either BLV6831C' or BLV6900C' (Fig.
1) detected no specific signals. Nested PCR with primer
BLV4761 paired with BLV6831C' or BLV6900C' resulted in
extremely weak signals, which probably represent a spuri-
ous reaction. Our primer BLV6831C', in combination with
BLV251, could amplify an abundant product of more than 2
kb from cDNA (representing unspliced genomic or envelope
single-spliced RNA) or from DNA extracted from FLK/BLV
cells, indicating that this primer works well. Thus, our
results indicated that mRNAs with a specific acceptor in the
5' end of the XBL-III ORF are either not expressed or
expressed at extremely low levels during BLV infection in
vivO.
As controls for the specificity of the PCR amplifications,
we performed PCR on mRNA, omitting the reverse tran-
scriptase step. No amplified products could be detected in
these samples (data not shown). Amplification of purified
genomic DNA from the same samples usually resulted in no
:i W...,qmqw,.,m "I
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amplified products. In certain samples, especially from
FLK/BLV cells, very large or very small bands could be
detected. These bands did not line up with any of the bands
having the predicted splice patterns for a Tax/Rex, XBL-IV,
or XBL-III mRNA, indicating that our bands amplified from
converted RNA are from spliced mRNA and not spurious
RNA transcribed from deleted proviruses. It has recently
been suggested that DNA representing spliced Tax/Rex
sequences could be detected in genomic DNA from BLV-
infected cattle (55). In our amplifications we did detect
certain bands in amplified DNA, but these bands had a
different size from those detected in the RNA samples.
Moreover, these bands did not react with the BLV probe
spanning the middle exon (data not shown). This suggests
that the sequences amplified from genomic DNA most
probably represent proviruses having most of the 3' end and
central region deleted. This would be consistent with the
structure of deleted proviruses reported previously (21).
Amplification of genomic DNA with primers BLV251 (locat-
ed in the R region) and BLV53OC' (located in the U5 region)
resulted in a positive band at 280 bases in all BLV-infected
samples examined and no reaction in control samples, indi-
cating that all infected samples contained BLV proviral
DNA (data not shown).
In summary, by using region-specific PCR we could detect
spliced mRNA having a splice pattern consistent with a
Tax/Rex mRNA and with alternatively spliced mRNAs
containing sequences in the XBL-IV ORF. An mRNA
containing sequences in the 5' end of the XBL-III ORF could
not be convincingly amplified and may not be expressed in
the samples we tested. The Tax/Rex and alternatively
spliced mRNAs could be detected at the highest levels in
BLV-infected cell cultures and at the next highest levels in
the 6-week p.i. samples from experimentally infected calves.
These mRNAs are also expressed, albeit at lower levels, in
naturally infected animals, where they could be detected by
nested PCR (Table 2).
Cloning and sequencing of alternatively spliced cDNAs. To
characterize specific mRNAs containing sequences in the
XBL-IV or XBL-III ORF, we performed nested PCR on
selected samples by using primers BLV221 or BLV251
together with BLV7557C' followed by nested PCR with
primers BLV251 and BLV7221C'. Probing of the amplifica-
tions with a full-length BLV probe or a probe spanning the
XBL-IV and XBL-III ORF resulted in several bands be-
tween 250 and 500 bp in the 6-week p.i. sample and in
samples from four of five experimentally infected calves at
28 weeks p.i. but in only a single band of approximately 410
bp in the cows with persistent lymphocytosis (Fig. 5; Table
2). The strongest signal was detected in the cows with
persistent lymphocytosis and in calf 353 at 28 weeks p.i.
Amplified products were cut with SacI and cloned into
pGEM3Z. Colonies were screened with a 32P-labeled full-
length BLV probe. From the pool of five calves infected for
6 weeks, a total of 32 clones were sequenced. Of these, 17
had a single splice joining nt 305 to nt 7018 (designated splice
pattern 305/7018), 10 had a single splice joining nt 502 to nt
7157 (splice pattern 502/7157), and 5 had two splices, one
joining nt 305 to nt 4649 and the other joining nt 4871 to nt
7018 (designated splice pattern RIII) (Fig. 1; Table 3). From
cow 9321 (with persistent lymphocytosis), 10 clones were
sequenced, and all had a single splice joining nt 502 to nt
7066 (designated splice pattern GIV) (Fig. 1; Table 3). To
confirm this unusual splice, amplifications were done on
RNA from another cow with persistent lymphocytosis (cow
9324) and on another RNA sample isolated from cow 9321 3
1 2 C 3
d }^-500 bp
-410 bp
-320 bp
-250 bp
FIG. 5. Southern blot analysis of PCR-amplified cDNAs. Total
RNAwas converted to cDNA and subjected to nested PCR by using
primers BLV251 and BLV7557C' followed by primers BLV251 and
BLV7221C'. Samples of the PCR products were electrophoresed
into agarose gels, Southern blotted onto nylon filters, and hybridized
with a full-length BLV probe as described in the text. Sizes of
amplified products are indicated in base pairs. Lanes: 1, calf 357
naturally infected with BLV; 2, calves experimentally infected with
BLV at 6 weeks p.i.; 3, cow 9321 with BLV-induced persistent
lymphocytosis; C, control calves.
months after the first sample. Sequence analysis of three
clones from each of these samples revealed the same splice
pattern (GIV), joining nt 502 to nt 7066, confirming this as a
genuine BLV splice pattern. Sequencing of clones derived
from two of the experimentally infected calves at 28 weeks
p.i. showed that two of three clones from calf 353 had the
GIV splice (nt 502 to nt 7066) while a single clone had the
double splice described above (RIII). One of three clones
from calf 354 had the nt 502-to-nt 7066 (GIV) splice, whereas
two clones had nt 305 joined to nt 7018 (305/7018) (Fig. 1).
In vitro translation and immunoprecipitation. To determine
whether the alternatively spliced mRNAs would encode
protein products, we performed in vitro transcription of
TABLE 3. Splice sites used in BLVD
Splice site Sequence Found in mRNA
305 1
5' donor GCGGUCAGguaaggoaag env, Tax/Rex, 305/7018
502 1CGGCGOCCucuagoggoc GIV, 502/7157
4871 1
UCAGAUGGguaaguouca Tax/Rex, RIII
1 4649
3' acceptor cauuucagAGGGCGGAGA env, Tax/Rex, RIII
1 7018
uccaaaagGUCCUGAUGA RIII, 305/7018
1 7066
gacauuccAGCCACAUCC GIV
1 7157
cuucuauuUCCACCUCGG 502/7157
1 7247
cuuuuaagCAAGUGIJUGU Tax/Rex
a Splice donor and acceptor sites used in the different BLV mRNAs are
listed. The sites used in the alternatively spliced mRNAs and the Tax/Rex
mRNA were determined in the present study, whereas sites used in the
envelope (env) mRNA were based on data in the literature (21, 80, 81, 108).
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FIG. 6. In vitro translation and immunoprecipitation of trun-
cated Rex encoded by the cDNAs. cDNAs were linearized and
transcribed in vitro by using T7 polymerase. Transcribed RNA was
translated in the presence of [3"S]cysteine and subjected to immu-
noprecipitation as described in the text. In vitro translation reaction
products (10 pul) were used for the immunoprecipitations except for
no. 4, in which 1 pul (lane dl) and 10 pul (lane d1o) were used.
Immunoprecipitated products were electrophoresed into an SDS-
15% polyacrylamide gel followed by fluorography. The positions of
molecular mass markers (in kilodaltons) are indicated. Truncated
Rex runs around 16 kDa, whereas full-length Rex runs around 22
kDa. Samples: 1, GIV plasmid cut with ClaI; 2, GIV plasmid cut
with EcoRI; 3, RIII plasmid cut with EcoRI; 4, BLV Rex plasmid
cut with EcoRI. Antibodies for precipitations: a, preimmune rabbit
1 serum; b, preimmune rabbit 2 serum; c, rabbit 1 immunized with
the GIV peptide as described in Materials and Methods; d, rabbit
anti-Rex serum.
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FIG. 7. In vitro transcription and translation of cDNA clones.
cDNAs were linearized and transcribed in vitro by using T7 poly-
merase. Transcribed RNAwas translated in the presence of [3H]leu-
cine, and samples were electrophoresed into an SDS-15% polyacryl-
amide gel followed by fluorography. The positions of molecular
mass markers (in kilodaltons) are indicated. Samples: 1, RIII
plasmid cut with ClaI; 2, no RNA added; 3, GIV plasmid cut with
ClaI; 4, splice 305/7018 plasmid cut with ClaI; 5, splice 502/7157
plasmid cut with ClaI; 6, splice 305/7018 plasmid cut with EcoRI; 7,
splice 502/7157 plasmid cut with EcoRI.
demonstrated (Fig. 8, lane 3b). The immunoprecipitation was
specific because no products were detected with preimmune
sera or with the anti-Rex antibody (Fig. 8). The apparent
molecular mass of 17 kDa of the GIV protein is in good
agreement with the estimated mass (11.6 kDa), considering
the apparent 16-kDa mobility of the truncated Rex protein
(estimated size, 13.1 kDa).
reconstructed cDNAs in pGEM4Z plasmids linearized with
ClaI or EcoRI followed by in vitro translation in the pres-
ence of [3H]leucine or [35S]cysteine. Translation of full-
length constructs (cut with EcoRI at nt 7924) resulted in an
abundant protein product from all the alternatively spliced
mRNAs. This product had a molecular mass of ca. 16 kDa,
comigrated with truncated Rex from a Rex-splice construct,
and could be specifically immunoprecipitated by antibodies
to the C-terminal part of Rex (Fig. 6). This indicated that the
alternatively spliced mRNAs all expressed truncated Rex
initiating at one of the internal AUGs in the Rex ORF.
Analysis of the coding regions of the RIII and GIV con-
structs indicated that these mRNAs could potentially ex-
press additional proteins (Fig. 1). Therefore, these con-
structs were cut by ClaI (which cuts at nt 7318) to avoid
expression of the truncated Rex proteins that obscured the
detection of additional small proteins. Translation of these
constructs resulted in a fairly abundant product from the
RIII mRNA construct. This product migrated as a doublet
with a molecular mass of around 6 to 8 kDa (Fig. 7). This is
in fairly good agreement with an estimated molecular mass
of 5.5 kDa. No additional products could be directly ob-
served in translated RNA from the GIV construct (Fig. 7).
However, immunoprecipitation with an antibody directed
against a synthetic peptide in the XBL-IV ORF resulted in a
very weak product migrating at around 17 kDa. By increasing
the amount of translation reaction 10-fold, the immunoprecip-
itation of this 17-kDa GIV product could be convincingly
1 2 3
a b cl a b c 1a b c
66 k- ......
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FIG. 8. In vitro translation and immunoprecipitation of proteins
encoded by the cDNAs. cDNAs were linearized and transcribed in
vitro by using T7 polymerase. Transcribed RNA was translated in
the presence of [35S]cysteine and subjected to immunoprecipitation
as described in the text. In vitro translation reaction products (100
,ul) were used for the immunoprecipitations, except for no. 1, for
which 10 p.l was used. Immunoprecipitated products were electro-
phoresed into an SDS-12% polyacrylamide gel followed by fluorog-
raphy. The positions of molecular mass markers (in kilodaltons) are
indicated. Samples: 1, BLV Rex plasmid cut with EcoRI; 2, RIII
plasmid cut with ClaI; 3, GIV plasmid cut with ClaI. Antibodies for
precipitations: a, preimmune rabbit 1 serum; b, rabbit 1 immunized
with the GIV peptide as described in Materials and Methods; c,
rabbit anti-Rex serum.
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In summary, the in vitro data indicated that the alternative
spliced mRNAs, as described for the Tax/Rex mRNA (42,
76, 77), can express truncated Rex protein originating at one
of the multiple AUGs in the Rex ORF. In addition, the RIII
mRNA expresses a protein of 6 to 8 kDa and the GIV mRNA
can express, albeit at low levels, a protein of 17 kDa.
CAT assays. A potential effect on LTR-driven transcrip-
tion of the RIII and GIV proteins was examined by transient
cotransfection with a BLV-LTR-CAT reporter construct
into CRFK cells. These studies indicated that the GIV
protein transactivated expression from the BLV-LTR by
two- to threefold while the RIII protein had no effect. Under
the same conditions, the BLV-Tax expression construct
transactivated LTR-driven transcription by 200-fold (data
not shown).
DISCUSSION
Using region-specific PCR, we have shown alternative and
complex splicing of BLV mRNA. In infected cattle we could
detect spliced mRNA with a splice pattern consistent with a
Tax/Rex mRNA and at least four alternatively spliced
RNAs, of which two encoded hitherto unrecognized BLV
proteins, designated RIII and GIV. The Tax/Rex and alter-
natively spliced mRNAs could be detected at the highest
levels in BLV-infected cell cultures and at the next highest
levels in the 6-week p.i. samples from experimentally in-
fected calves. These mRNAs are also expressed, albeit at
lower levels, in naturally infected animals, in which they
could be detected by using nested PCR. Interestingly, the
GIV mRNA was specifically detected in naturally infected
cows with persistent lymphocytosis and in two of five calves
at 28 weeks after experimental infection with BLV. Further-
more, the calf with the strongest signal for GIV (calf 353)
also had the highest lymphocyte counts (Fig. 2A). These
data may suggest a correlation between expression of the
GIV product and development of persistent lymphocytosis.
In situ hybridization analysis of PBMC showed the pres-
ence of a very few positive cells in the experimentally
infected calves early after infection (2 and 6 weeks p.i.). No
positive PBMC could be directly detected in the experimen-
tally infected calves at 19 weeks p.i. or in a naturally infected
cow with persistent lymphocytosis. Interestingly, incubation
of the PBMC from these animals in PBS with 10% fetal calf
serum for a few hours resulted in up to 0.1% positive cells in
the experimentally infected calves and in approximately 20%
positive PBMC from the cow with persistent lymphocytosis.
Also, the level of serum-induced BLV transcription in the
individual cells was highest in the cow with persistent
lymphocytosis. These results are in good agreement with in
situ hybridization data from BLV infection in sheep, pub-
lished by Lagarias and Radke (65). Whether this restriction
of BLV expression in vivo is mediated by antibodies against
the viral surface glycoprotein, as described for HTLV (104),
or by a plasma repressing factor (30, 49, 50) is currently
unknown. Nevertheless, our in situ hybridization data indi-
cated that our normal procedure for isolating PBMC did not
induce BLV expression and hence that our PCR experiments
detected low levels of BLV RNA present in vivo in PBMC
with severely restricted BLV expression.
In vitro translation experiments and examination of the
coding potential of the alternatively spliced mRNAs indi-
cated that all four could encode an N-terminally truncated
form of Rex starting at one of the multiple internal AUGs in
the Rex ORF (first possible AUG at nt 7280). Such a
truncated form of Rex could also be encoded by the Tax/Rex
GIV
1 LACTRVCFLS YFLFLAARAL SFGAQPHPAA FGPPFLTVPI KSLPFPQRLP
51 LHLLFPPRHR LPRRALRALR DPLPDNDKII SCLLSKCCWL GAPLSTCLPG
101 PGFVQ
RIII
1 MPKERRSRRR PQPIIRWVLM NVFPCNKPQQ RHSSHIQQHL GRLF
FIG. 9. Amino acid sequences of the potential GIV and RIII
proteins. The hydrophobic leader from exon 1 in the GIV protein
has a double underline, and the potential proteolytic cleavage sites
are indicated by arrows. The 7-amino-acid stretch in GIV with
homology to members of the Myb family of proteins has a single
underline. The arginine-rich potential targeting signal in the GIV
protein is indicated in boldface, as are the 17 amino acids of exon 1
in the RIII protein identical to the nucleolus-targeting signal and
RNA-binding motif in exon 1 of Rex.
mRNA. The size of the truncated Rex product(s) estimated
on gels was around 16 kDa, and the theoretical size would be
13.1 kDa or less depending on the AUG used. This difference
in apparent mobility correlates well with results published by
others (77). The 305/7018 and 502/7157 RNAs (Fig. 1) appar-
ently encode only the truncated Rex protein. mRNAs en-
coding only truncated Rex have been shown for HTLV (15,
42, 76), although no specific function has been shown for
such a truncated Rex protein that lacks the nucleolus-
targeting and RNA-binding motif.
In addition to truncated Rex, the GIV mRNA could
encode a very interesting protein. The use of the alternative
donor site at nt 502 incorporates an mRNA leader that
potentially could initiate protein translation at one of the
multiple CUGs in frame 1. The CUG at nucleotide 430
(CGUCUGG) is in a reasonable context, and we speculated
that the GIV mRNA could encode a protein starting at this
CUG. The murine leukemia retroviruses initiate glycosy-
lated Gag protein (78), equine infectious anemia retrovirus
initiates translation of Tat protein from CUGs in this region
of their genomes (39, 92), and initiation at non-AUGs has
also been described for other viral (11, 12, 18, 68) and
cellular (52) proteins. Initiation at the CUG at nt 430 could
give a hypothetical protein of 24 amino acids in frame 1
linked to 81 amino acids in the XBL-IV ORF (frame 3) at nt
7066 until terminated at nt 7307 (Fig. 9). This gives a total of
105 amino acids with a molecular mass of 11.6 kDa. Further-
more, this hypothetical protein has a Rex-like, potential
nucleolus-targeting and RNA-binding motif consisting of 6
arginines in a stretch of 13 amino acids (Fig. 9). Translation
of the GIV RNA followed by immunoprecipitation with an
antibody directed against a peptide in the XBL-IV ORF
resulted in a weak band migrating at 17 kDa. This result
suggests that the GIV mRNA does express a GIV protein,
and, moreover, the low level of translation is in agreement
with a potential suboptimal CUG initiation codon. Computer
analysis of the potential GIV protein initiating at the CUG at
nt 430 indicated that the first 24 amino acids encoded in
reading frame 1 had the characteristics of a hydrophobic
leader peptide (Fig. 9). Furthermore, the analysis indicated
potential proteolytic cleavage sites between amino acids 21
and 22 or 23 and 24. If this is the case, the final GIV protein
would consist of the 81 amino acids from the XBL-IV ORF.
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This ORF does not contain any potential N-linked glycosy-
lation sites, indicating that the functional significance of the
potential leader peptide is not glycosylation. This is in
contrast to the glycosylated Gag protein of the murine
leukemia viruses, which uses a suboptimal CUG codon to
add a leader peptide transporting the protein to the endo-
plasmic reticulum for glycosylation (32, 78).
Our theory of the GIV protein being expressed in vivo is
supported by the fact that the nucleotide sequence of the
XBL-IV ORF is highly conserved (more than 99%) between
the two published sequences of BLV (80, 81, 89). Consider-
ing the highly variable nature of retroviruses, it seems
unlikely that this region would be so highly conserved unless
it encoded a functional protein. To get a possible indication
of potential function of the GIV protein, we searched the
NBRF and Swiss-Prot (release 20) protein data bases for
amino acid sequence homologies. Only limited, but interest-
ing, areas of homology between the BLV GIV amino acid
sequence and proteins in the data base could be demon-
strated. The potential role of GIV in tumorigenesis is
strengthened by the observed identity of the 7-amino-acid
stretch ProIleLysSerLeuProPhe to members of the Myb
protein family of proto-oncogenes (57, 66, 97) (Fig. 9).
Multiple Myb-binding motifs can be found in the BLV
enhancer region, and it has been shown that Myb can
transactivate the HTLV and HIV LrRs (20, 33, 34). Thus, it
is possible that BLV transcription is regulated by Myb or,
alternatively, that cellular genes are regulated by the poten-
tial GIV protein. In any case, the homology is interesting
considering the role of Myb in myeloid and lymphoid regu-
lation and in leukemia. The GIV protein was also found to be
55% homologous, over an 18-amino-acid stretch, to the
measles virus phosphoprotein P. This protein binds to RNA
and is probably part of the transcription complex initiating
measles virus transcription (13). Taken together, the amino
acid homologies of the GIV protein suggest a potential role
of this hypothetical protein in viral or cellular transcriptional
regulation and perhaps in tumorigenesis.
The RIII mRNA could potentially encode a protein start-
ing at the Rex/envelope AUG at nt 4821, continuing for 17
amino acids in frame 3 spliced to the 3' end of the XBL-III
ORF (frame 1) at nt 7018, and continuing in this frame for 27
amino acids until terminated at nt 7098. The protein would
consist of 44 amino acids (Fig. 9) and have a calculated
molecular mass of 5.5 kDa. A protein doublet of 6 to 8 kDa
could be shown by in vitro translation of the RIII RNA. The
RIII protein contains a potential phosphorylation site and
the two bands could correspond to phosphorylated and
unphosphorylated forms of RIII. Alternatively, the smaller
form could be a proteolytic cleavage product.
Comparison of the C-terminal 27-amino-acid sequence of
the RIII protein with the data bases did not show any
significant homologies. The amino-terminal part of the RIII
protein has the same nucleolus-targeting and RNA-binding
motif as Rex (Fig. 9). Thus, it is likely that the RIII protein
can bind to the Rex-responsive element RexRE (10, 37, 101).
This interaction could potentially act as a transdominant
repressor of Rex function as described for C-terminally
truncated forms of Rex (10, 19, 53, 82). Alternatively, the
function of RIII could be significantly different depending on
a specific functional role of the 27 amino acids in the XBL-III
ORF. We are currently designing assay systems to test for a
possible role of the RIII protein on Rex regulation of BLV
expression.
Some characteristics of the potential products of GIV and
RIII are shown in Table 4, together with similar potential
TABLE 4. Characteristics of known and potential BLV and
HTLV regulatory proteinsa
Mol Potential No. of cysteines!
Protein mass PI1 nucleolus- Repeated total no. of
(kDa) targeting leucines amino acids
signal
BLV Rex 16.5 11.2 Yes Yes 4/156
BLV RIII 5.5 12.7 Yes Yes 1/44
BLV GIV 11.6 10.6 Yes Yes 6/105
HTLV Rex 20.5 9.6 Yes Yes 6/189
HTLV Rof 17.4 13.0 Yes Yes 1/152
HTLV Tof 26.7 12.9 Yes Yes 9/241
HIV Rev 13.3 9.5 Yes Yes 3/118
HIV Vpr 11.3 8.7 Yes Yes 1/96
BLV Tax 34.3 6.5 No Yes 12/309
HTLV Tax 39.5 6.5 No Yes 8/353
a The primary amino acid sequences of the BLV, HTLV, and HIV proteins
shown were extracted from sequences in GenBank or from published data
(27). The molecular mass and isoelectric point of the proteins were calculated
by using the Microgenie or PC/Gene programs. A potential nucleolus-
targeting signal was determined by comparison with the known nucleolus-
targeting signals present in Rex or Tof (27, 54, 64, 67, 82). The Tax proteins
do not have any obvious nucleolus-targeting signals, but regions with nuclear
localization signals have been described (102). The number of cysteines and
total number of amino acids in the proteins are indicated.
products of HTLV (27), the Rex and Tax proteins of BLV
and HTLV, and Rev and Vpr of HIV for comparison. The
characteristics summarized in Table 4 indicate that the
potential new proteins of BLV and HTLV, together with the
Rex proteins of BLV and HTLV and Rev and Vpr of HIV,
have several similar features. This may suggest that these
proteins belong to a common family of complex retrovirus
regulatory proteins. The features linking these proteins are
as follows: relatively small size (i.e., less than 30 kDa),
highly basic, presence of an arginine-rich positively charged
stretch characteristic of a nucleus- or nucleolus-targeting
signal (shown to be necessary for Rex/Rev function [54, 64,
67, 82]), stretches of repeated leucine or isoleucine residues
resembling leucine zipper motifs to some degree (63, 74, 90,
106, 112), and, in the Rex, GIV, and HTLV Tof proteins, the
presence of multiple cysteines. These features suggest that
the putative new proteins ofBLV and HTLV may play a role
in nucleic acid binding and in viral and cellular regulation.
Alignment of the BLV and HTLV proteins did not show a
high degree of homology among the proteins (less than 30%
homology). However, this is also true for the Rex and Tax
proteins of BLV and HTLV, although these proteins have
been shown to have similar functions in the two viruses.
Thus, functional motifs may be more important than amino
acid sequence similarity in assessment of the relatedness of
this group of proteins.
Transient-expression experiments indicated that the RIII
protein had no effect on the LTR-driven expression of BLV
whereas the GIV protein could transactivate the LTR by
two- to threefold. This low level of transactivation resembles
the degree of transactivation observed with Vpr activation of
the HIV LTR (28) and with Myb activation of the HTLV or
HIV LTR (20, 33, 34) or Myb activation of cellular genes like
CD4 and Myc (100, 113). This may indicate that the function
of the GIV protein may be as a transactivator of certain
genes, although the observed level on the BLV LTR seems
extremely low compared with Tax transactivation. Since
expression of the GIV mRNA also correlated with levels of
virus-infected cells, the possible effect of GIV in tumorigen-
esis may be indirect. That is, GIV may increase virus
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expression of other viral proteins, which may have a more
direct effect on cell proliferation. We tested the activating
potential of the RIII and GIV proteins in a feline kidney cell
line that has shown great versatility for testing a diverse
range of transactivating proteins (our unpublished observa-
tions). It is possible that this particular cell line does not
support full functional activity of the RIII and GIV proteins
or that the main functional capabilities of these proteins are
not directed at regulation of the BLV LTR.
Analysis of splice donor and acceptor sites of the alterna-
tively spliced mRNAs revealed several interesting findings.
The donor at nt 305 used in the 305/7018 mRNA (Fig. 1) and
as the first donor in the RIII mRNA has the canonical GU as
the 5' nucleotides in the spliced-out intron and is identical to
the donor used in the single spliced envelope mRNA and the
first donor in the Tax/Rex mRNA (108) (Table 3). The
second donor in the RIII mRNA at nt 4871 is also identical to
the second donor of the Tax/Rex mRNA and fits well with
established consensus (71). The donor at nt 502 in the
502/7157 and the GIV mRNA is quite unusual in having UC
as the first two bases in the intron (Table 3). This donor was
used in combination with two different acceptors at nt 7066
or 7157 (Fig. 1; Table 3). These two acceptors are also quite
unusual in having a CC (nt 7066) or a UU (nt 7157) dinucle-
otide as the 3' bases in the intron. However, these donors
and acceptors were used in RNA samples from several
individual animals, indicating that such mRNAs are exam-
ples ofbona fide BLV transcripts in vivo. The acceptors at nt
4649 (RIII, Env, and Tax/Rex) and 7018 (RIII and 305/7018)
both fit well with established consensus having an AG as the
3' dinucleotide in the intron. Surprisingly, the RIII splice
pattern uses only a small fraction of the XBL-III ORF.
However, the use of an RIII acceptor at nt 7018 would be
likely if there is a stop signal in the XBL-III ORF at nt 6973
as described by Rice et al. (80, 81). Using our techniques, we
could not find any evidence for use of the theoretical splice
acceptor at the beginning of the XBL-III ORF at nt 6742 or
at the acceptor at nt 6824 described by Ciminale et al. (27).
The mechanisms involved in the use of alternative, and
unusual, splice sites are currently obscure. The use of splice
sites could be controlled by virus-encoded factors, as sug-
gested for HIV Rev (69), or could be determined by cellular
factors as described for several cellular genes (22, 29, 61,
72). Regardless of the mechanisms involved, it seems as if at
certain stages during BLV infection, the use of several,
suboptimal, splice donors and acceptors results in joining of
specific RNA sequences and generation of additional func-
tional mRNAs. In this context, generation of the RIII and
GIV mRNAs in infected cells may be important in the
pathogenesis of persistent lymphocytosis and eventually
leukemia in BLV-infected animals.
In conclusion, we identified alternatively spliced mRNAs
encoding potential new regulatory proteins of BLV. Com-
puter analysis revealed that the hypothetical new BLV
proteins share interesting features and homologies with
proteins involved in viral and cellular regulation. Further-
more, our studies may suggest that the GIV protein is
expressed in vivo and is involved in BLV-induced persistent
lymphocytosis. On the basis of the potential properties
discussed above, the GIV protein is a promising candidate
for a virally encoded protein involved in the BLV-induced
proliferation of B cells and, perhaps, in development of
leukemia.
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